Biocon buys back GE holding in IPO-bound Syngene
This article was originally published in Scrip
Executive Summary
GE Capital has divested its 7.69% holding in Biocon's research services arm, Syngene International – a unit which the Indian biopharmaceutical company hopes to take public.